iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
1.230
+0.030 (2.50%)
At close: Nov 28, 2025, 1:00 PM EST
1.219
-0.011 (-0.88%)
After-hours: Nov 28, 2025, 4:47 PM EST
iBio, Inc. Revenue
iBio, Inc. had revenue of $100.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $500.00K, up 185.71% year-over-year. In the fiscal year ending June 30, 2025, iBio, Inc. had annual revenue of $400.00K with 77.78% growth.
Revenue (ttm)
$500.00K
Revenue Growth
+185.71%
P/S Ratio
32.61
Revenue / Employee
$25,000
Employees
20
Market Cap
27.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 400.00K | 175.00K | 77.78% |
| Jun 30, 2024 | 225.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
| Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IBIO News
- 4 days ago - iBio to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 16 days ago - iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance - GlobeNewsWire
- 5 weeks ago - iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 5 weeks ago - iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025 - GlobeNewsWire
- 3 months ago - iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - iBio Announces Closing of $50 Million Public Offering - GlobeNewsWire
- 3 months ago - iBio Announces Pricing of $50 Million Public Offering - GlobeNewsWire